2017 American Transplant Congress
Systemic Immunosuppression in the Setting of Ocular Surface Stem Cell Transplantation.
1University of Cincinnati, Cincinnati, OH; 2Cincinnati Eye Institute, Cincinnati, OH
Purpose: To evaluate the success, tolerability, and side effects of systemic immunosuppression (SI) in patients undergoing ocular surface stem cell transplantation (OSST) under the SI…2017 American Transplant Congress
Medication Adherence and Medicare B Coverage Among Transplant Recipients.
Purpose: Impact of nonadherence among transplant recipients has been well documented as a significant contributor of allograft failure. Medicare covers immunosuppressive medications for eligible patients…2017 American Transplant Congress
Comparison of Long Term Survival Outcomes for Everolimus (EVR) vs. Mycophenolic Acid (MPA) Immunosuppressive Regimens Post Kidney Transplant.
In the US, MPA in combination with calcineurin inhibitors (CNI, tacrolimus [TAC] or cyclosporine A [CsA]) is the most commonly used maintenance immunosuppressive therapy post…2017 American Transplant Congress
More Than Renal Function: Use of Belatacept to Improve Drug Toxicities.
Background: Data with belatacept has demonstrated that patients on de novo belatacept have better renal function and improved patient and graft survival seven years post-transplant.…2017 American Transplant Congress
Cyclosporine Effects on Blood Pressure Are Exaggerated in Pubertal Girls After Renal Transplantation.
Hypertension is a common problem after renal transplantation. We investigated potential contributing factors for high blood pressure (BP) in 336 pediatric transplant recipients from the…2017 American Transplant Congress
Graft-versus-Host Disease Following Deceased Donor Liver Transplant.
Henry Ford Hospital, Detroit, MI
We reviewed our institutional experience with graft-versus-host disease (GVHD) following orthotopic liver transplantation (OLT). All OLT from 10/1/2013-10/1/2016 were reviewed. Five cases of GVHD were…2017 American Transplant Congress
Tacrolimus Time in Therapeutic Range Predicts Adverse Clinical Outcomes in the First Year of Kidney Transplant.
University of Colorado, Aurora, CO
Tacrolimus (TAC) has a narrow therapeutic range, with its upper bounds limited by serious toxicities while TAC minimization strategies have demonstrated immunologic risk. Monitoring the…2017 American Transplant Congress
Differential Effects of the Novel ATP-Competitive mTOR Inhibitor (TORKinib) AZD2014 and Rapamycin on Alloimmunity and Transplant Survival.
Surgery, Thomas Starzl Transplantation Institute, Pittsburgh, PA
Background: Rapamycin (RAPA), is an immunosuppressive agent that inhibits the mechanistic target of Rapamycin (mTOR), the kinase subunit of two mTOR- containing complexes (mTORC1 and…2017 American Transplant Congress
Inhibition of Liver Natural Killer Cells Activation Through Co-Transplantation of Pre-Activated Mesenchymal Stem Cells Contributes to Improvement of Islet Graft Survival.
Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan
Introduction: We have previously reported that enhancement of TNF-related apoptosis-inducing ligand (TRAIL)-mediated liver NK-cell activity after intraportal islet transplantation (IT) inhibits engraftment of islets. Recently,…2017 American Transplant Congress
Kidney-Specific Immunosuppression without Adverse Systemic Effects.
Purpose: Immunosuppressive therapy is often accompanied by severe adverse effects. To overcome this, the aim of this study was the evaluation of a kidney-specific drug…
- « Previous Page
- 1
- …
- 96
- 97
- 98
- 99
- 100
- …
- 138
- Next Page »